Drug intelligence / Profile preview

n-ethylmaleimide

Development stage
Unknown
Modality
Small Molecules
01

Overview

N-Ethylmaleimide (NEM) is a small molecule derived from maleic acid and classified as a maleimide. It is a highly reactive Michael acceptor that selectively alkylates thiol (sulfhydryl) groups in proteins and peptides—most notably cysteine residues—forming stable thioether bonds. This reaction is virtually irreversible under physiological conditions. NEM acts as an irreversible inhibitor of all cysteine peptidases by covalently modifying the active site thiol group. It has been widely used in biochemical research to probe the functional role of protein thiols and to inhibit enzymes such as deubiquitinases and certain kinases. In addition to its use in protein modification studies (e.g., blocking de-sumoylation or DNA fragmentation), it serves roles in bioconjugation chemistry for attaching biomolecules to surfaces or other molecules and has applications in polymer synthesis and diagnostics[1][4][5][6][7].

Other names
n-ethylmaleimideethylmaleimide1-ethyl-1H-pyrrole-2,5-dioneN-EthylmaleinimideNEMI/NEMusafb-121usafb121usafb 121

Beyond the preview

Go deeper on n-ethylmaleimide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-ethylmaleimide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call